59. Betteridge, DJ and Gibson, JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabetic Medicine Volume 24 Issue 5, Pages 541 - 549

60. Campeau, L Knatterud, GL et al. The Post Coronary Artery Bypass Graft Trial Investigators. The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-Vein Coronary-Artery Bypass Grafts. N Engl J Med 1997; 336:1839-1840, Jun 19, 1997 13

61. Pitt B, Waters D, et al. Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease. N Engl J Med 1999;341:70 14

62. Barth JD, Zonjee MM.et al. The REGRESS Research Group. Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. Can J Cardiol. 1992 Nov;8(9):925-32.

63. Furberg, CD Adams Jr, HP et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90:1679-1687 15

64. Waters, D. Higginson, L. et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68 16

65. Waters D, Higginson L, et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy.Circulation 1995;92:2404-10 17

66. Pitt B.; Mancini GBJ. et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I) : reduction in atherosclerosis progression and clinical events. Journal of the American College of Cardiology. 1995, vol. 26, no5, pp. 1133-1139 ISSN 0735-1097

67. Crouse J R; Byington R. P. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II) Am j card. 1995, vol. 75, no7, pp. 455-459

68. Salonen, R, Nyssonen, K et al. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am-J-Cardiol. 1995 Sep 28; 76(9): 34C-39C

69. David H. Blankenhorn; Stanley P et al. The MARS Research Group. Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS). Annals of Internal Medicine. 1993. Volume 119 Issue 10. Pages 969-976 18

70. Smilde TJ, Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577–81

71. Hedblad B, Wikstrand J, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001 Apr 3;103(13):1721-6.

72. Sirtori, C.R, Bianchi, G.Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. The International Journal of Cardiac Imaging Volume 11, Supplement - 2 / junio de 1995. pp 119-124

73. Yasunori Sawayama, Chie Shimizu, et al. Fukuoka atherosclerosis trial (FAST) Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia J Am Coll Cardiol, 2002; 39:610-616 19

74. Taylor, AJ; Kent, SM; et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol. A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness Circulation. 2002;106:2055. 20

75. Taylor, AJ; Kent, SM; et al.Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2 A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins. Circulation. 2004;110:3512-3517 21

76. Steven E. Nissen; E. Murat Tuzcu, et al. for the REVERSAL Investigators Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. A Randomized Controlled Trial JAMA. 2004; 291:1071-1080. 22

77. Pedersen, TR; Faergeman, O. et al. for the IDEAL study group. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. JAMA. 2005;294:2437-2445. 23

78. Nissen S. Design and methodology of a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden: The ASTEROID study. Atherosclerosis Supplements 2003;4(2);27

79. Steven E. Nissen, MD et al. The ASTEROID Trial. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis.JAMA. 2006;295:

80. Crouse JR 3rd, Raichlen JS, Riley WA, et al. METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297:1344–53. 24

81. Hatsukami TS, Zhao XQ, Yuan C, et al. Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenosis. Atherosclerosis Supplements 2001;2(2):47-8

82. Lee, CH; de Feyter,P et al. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS) Heart. 2004 October; 90(10): 1156–1161. doi: 10.1136/hrt.2003.027284. 25

83. Zheng Zhou, Elham Rahme et al. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.CMAJ. 2005 April 26; 172(9): 1187–1194. 26

84. Respecto a estudios del papel de las estatinas en la osteogénesis pueden consultarse:

 

·         Mohammed H. Moghadasian, Jiri J. Frohlich, Statins and bonesCan.Med.As.Jour. • MAR. 20, 2001; 164 (6)

·         Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H.HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283:3205-10.

·         Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283:3211-6.

·         Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355:2185-8.

·         Van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C.Use of statins and risk of fractures. JAMA 2001; 285:1850-5.

·         LaCroix AZ, Cauley JA, Jackson R y col. Does statin use reduce risk of fracture in postmenopausal women? J Bone Miner Res 2000; 15 (suppl1): S 155.

 

85. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002 Sep;52(3):346-50.

86. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000 Nov 11; 356(9242):1627-31.

87. Michael Donnino and Michael Cocchi, Beth Israel Deaconess Medical Center. Boston, Massachusetts Study of Statin Therapy in the Treatment of Sepsis Estudio randomizado doble ciego iniciado en febrero del 2008. Información 28

88. Danai Khemasuwan, M.D et al. CHEST 2008: Statins Lower Risk of Deep Vein Thrombosis. Study of patients with solid organ tumors associates statins with a nearly threefold lower risk

89. E Galli y L Feijoo. CITOCROMO P-450 Y SU IMPORTANCIA CLÍNICA. Revista de Neuro-Psiquiatría 2002; 65: 187-201. Último acceso 4 de marzo, 2008. 29

90. Véase Guía de Prescripción Terapéutica. Información de medicamentos autorizados en España. (Revisado el 29, septiembre, 2.008). 30

91. Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. Curr Med Res Opin. 2004 Jul; 20(7):1087-94.

92. Davidson MH.. Safety profiles for HMG-CoA reductase inhibitors. Drugs. 2001;61:1917-26.

93. Thompson P, Clarkson P, Karas R. Statin-associated myopathy. JAMA. 2003; 289:1681-90.

94. Baigent C, Keech A et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of ata from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78